Critical issues in peripheral arterial disease detection and management: a call to action.

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ (2008) 7.47

Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ (2004) 2.55

Ankle Brachial Pressure Index: identifying cardiovascular risk and improving diagnostic accuracy. J R Soc Med (2007) 2.07

Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care (2008) 2.04

Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease. J Appl Physiol (1985) (2011) 1.52

Molecular imaging of bone marrow mononuclear cell survival and homing in murine peripheral artery disease. JACC Cardiovasc Imaging (2012) 1.49

Cell therapy of peripheral arterial disease: from experimental findings to clinical trials. Circ Res (2013) 1.43

Blood Oxygenation Level-Dependent CMR-Derived Measures in Critical Limb Ischemia and Changes With Revascularization. J Am Coll Cardiol (2016) 1.40

Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol (2013) 1.38

The 9p21 myocardial infarction risk allele increases risk of peripheral artery disease in older people. Circ Cardiovasc Genet (2009) 1.27

Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. Circ Cardiovasc Genet (2011) 1.26

Ankle brachial pressure index (ABPI): An update for practitioners. Vasc Health Risk Manag (2009) 1.23

Peripheral arterial disease: lack of awareness in Canada. Can J Cardiol (2009) 1.23

Plasma nitrite response and arterial reactivity differentiate vascular health and performance. Nitric Oxide (2009) 1.20

Lower-limb vascular imaging with acoustic radiation force elastography: demonstration of in vivo feasibility. IEEE Trans Ultrason Ferroelectr Freq Control (2009) 1.10

Genetic susceptibility to peripheral arterial disease: a dark corner in vascular biology. Arterioscler Thromb Vasc Biol (2007) 1.09

Low-dose Paclitaxel-coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: 1-year Results of the ILLUMENATE European Randomized Clinical Trial. Circulation (2017) 1.08

Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol (2012) 1.04

Injectable skeletal muscle matrix hydrogel promotes neovascularization and muscle cell infiltration in a hindlimb ischemia model. Eur Cell Mater (2012) 1.03

Ankle-brachial index as a predictor of coronary disease events in elderly patients submitted to coronary angiography. Clinics (Sao Paulo) (2013) 1.01

Distribution of the ankle-brachial index and associated cardiovascular risk factors in a population of middle-aged and elderly koreans. J Korean Med Sci (2005) 1.01

Oxidative damage and myofiber degeneration in the gastrocnemius of patients with peripheral arterial disease. J Transl Med (2013) 0.96

Targeted screening for peripheral arterial disease in general practice: a pilot study in a high risk group. Br J Gen Pract (2007) 0.96

Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv (2014) 0.94

Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort. Clin Res Cardiol (2009) 0.94

Peripheral arterial disease in patients presenting with acute coronary syndrome in six middle eastern countries. Int J Vasc Med (2011) 0.93

Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease. Atherosclerosis (2008) 0.92

Functional haplotypes of the hTERT gene, leukocyte telomere length shortening, and the risk of peripheral arterial disease. PLoS One (2012) 0.91

Ankle-Brachial Index determination and peripheral arterial disease diagnosis by an oscillometric blood pressure device in primary care: validation and diagnostic accuracy study. BMJ Open (2012) 0.90

Contemporary risk factor control and walking dysfunction in individuals with peripheral arterial disease: NHANES 1999-2004. Atherosclerosis (2008) 0.89

Plasma nitrite flux predicts exercise performance in peripheral arterial disease after 3months of exercise training. Free Radic Biol Med (2010) 0.89

Prevalence and risk factors of asymptomatic peripheral arterial disease in patients with COPD in Taiwan. PLoS One (2013) 0.88

Cost-effective, risk-free, evidence-based medicine. Arch Intern Med (2003) 0.88

Critical Limb Ischemia: Current Trends and Future Directions. J Am Heart Assoc (2016) 0.87

Profile of cardiovascular risk factors and mortality in patients with symptomatic peripheral arterial disease. Clinics (Sao Paulo) (2009) 0.87

Peripheral arterial disease: a high risk - but neglected - disease population. BMC Cardiovasc Disord (2005) 0.87

Lower limb arterial incompressibility and obstruction in rheumatoid arthritis. Ann Rheum Dis (2004) 0.86

Systemic risk score evaluation in ischemic stroke patients (SCALA): a prospective cross sectional study in 85 German stroke units. J Neurol (2007) 0.85

Renal vasoconstriction is augmented during exercise in patients with peripheral arterial disease. Physiol Rep (2013) 0.85

Significant correlation between ankle-brachial index and vascular access failure in hemodialysis patients. Clin J Am Soc Nephrol (2009) 0.84

Associations of calf skeletal muscle characteristics and peripheral nerve function with self-perceived physical functioning and walking ability in persons with peripheral artery disease. Vasc Med (2011) 0.84

Peripheral artery disease: potential role of ACE-inhibitor therapy. Vasc Health Risk Manag (2008) 0.83

A new efficient trial design for assessing reliability of ankle-brachial index measures by three different observer groups. BMC Cardiovasc Disord (2006) 0.83

Clinical application of vascular regenerative therapy for peripheral artery disease. Biomed Res Int (2013) 0.83

Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets (2009) 0.83

Trimethylamine N-Oxide and Mortality Risk in Patients With Peripheral Artery Disease. J Am Heart Assoc (2016) 0.82

The association of biomarkers of iron status with peripheral arterial disease in US adults. BMC Cardiovasc Disord (2009) 0.82

Endothelial dysfunction and brachial intima-media thickness: long term cardiovascular risk with claudication related to peripheral arterial disease: a prospective analysis. PLoS One (2014) 0.82

Fast plaque burden assessment of the femoral artery using 3D black-blood MRI and automated segmentation. Med Phys (2011) 0.82

The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis (2013) 0.81

Long-term survival after initial hospital admission for peripheral arterial disease in the lower extremities. BMC Cardiovasc Disord (2009) 0.81

Nitrate ingestion: a review of the health and physical performance effects. Nutrients (2014) 0.80

Local association between endothelial dysfunction and intimal hyperplasia: relevance in peripheral artery disease. J Am Heart Assoc (2015) 0.80

Novel risk factors for premature peripheral arterial occlusive disease in non-diabetic patients: a case-control study. PLoS One (2013) 0.79

Screen or not to screen for peripheral arterial disease: guidance from a decision model. BMC Public Health (2014) 0.79

Meeting the challenge of peripheral arterial disease. Arch Intern Med (2003) 0.78

Association of impaired fasting glucose, diabetes and their management with the presentation and outcome of peripheral artery disease: a cohort study. Cardiovasc Diabetol (2014) 0.78

Computational Network Model Prediction of Hemodynamic Alterations Due to Arteriolar Rarefaction and Estimation of Skeletal Muscle Perfusion in Peripheral Arterial Disease. Microcirculation (2015) 0.77

Self-reported peripheral arterial disease predicts future vascular events in a community-based cohort. J Gen Intern Med (2008) 0.77

Evaluation of asymptomatic peripheral arterial disease by ankle- brachial index in patients with concomitant coronary arterial disease. Int Cardiovasc Res J (2012) 0.77

Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease. Exp Ther Med (2013) 0.77

Measurements of CD34+/CD45-dim Stem Cells Predict Healing of Diabetic Neuropathic Wounds. Diabetes (2015) 0.76

Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics. Front Pharmacol (2015) 0.76

Study of risk factors associated with peripheral arteriopathy in Japanese-Brazilians from Bauru (SP). Arq Bras Cardiol (2014) 0.76

Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia. Gene Ther (2015) 0.75

Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent. Immunol Endocr Metab Agents Med Chem (2014) 0.75

Depression and screening cardiovascular events. J Gen Intern Med (2008) 0.75

Association of peripheral arterial and cardiovascular diseases in familial hypercholesterolemia. Arq Bras Cardiol (2014) 0.75

Peripheral arterial disease in the Middle East: Underestimated predictor of worse outcome. Glob Cardiol Sci Pract (2013) 0.75

Ozonized autohemotransfusion does not affect arterial vasodilation in patients with peripheral arterial disease. Int J Angiol (2007) 0.75

Serum N-terminal pro-B-type natriuretic peptide levels are associated with functional capacity in patients with peripheral arterial disease. Angiology (2011) 0.75

Peripheral arterial disease: still on the periphery? BMJ (2006) 0.75

An evaluation of ankle-brachial blood pressure index in adult Nigerians with sickle cell anaemia. Cardiovasc J Afr (2012) 0.75

Gaps in awareness of peripheral arterial disease in Sri Lanka: a cross sectional study. BMC Public Health (2016) 0.75

Association of adiponectin with peripheral arterial disease and mortality in nondiabetic hemodialysis patients: Long-term follow-up data of 7 years. J Res Med Sci (2016) 0.75

Association Between Ankle-Brachial Index and Coronary Lesions Assessed by Coronary Angiography. Cardiol Res (2015) 0.75

A six-year study of diagnostic lower extremity imaging practice patterns and outcomes in the Veterans Affairs health care system. Int J Angiol (2008) 0.75

Diastolic versus systolic ankle-brachial pressure index using ultrasound imaging & automated oscillometric measurement in diabetic patients with calcified and non-calcified lower limb arteries. BMC Cardiovasc Disord (2016) 0.75

Predicting long-term prognosis in stable peripheral artery disease with baseline functional capacity estimated by the Duke Activity Status Index. Am Heart J (2016) 0.75

Spontaneous and coherent anti-Stokes Raman spectroscopy of human gastrocnemius muscle biopsies in CH-stretching region for discrimination of peripheral artery disease. Biomed Opt Express (2015) 0.75

Twenty-Year Predictors of Peripheral Arterial Disease Compared With Coronary Heart Disease in the Scottish Heart Health Extended Cohort (SHHEC). J Am Heart Assoc (2017) 0.75

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74

Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol (2002) 35.63

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation (2009) 35.24

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation (2003) 23.97

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation (2004) 20.67

Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation (2010) 19.30

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation (2005) 18.90

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 16.52

Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28

Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90

Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA (2009) 13.69

ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation (2006) 13.21

Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation (2004) 13.07

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44

Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31

Human genetic variation and its contribution to complex traits. Nat Rev Genet (2009) 12.11

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61

ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 11.49

Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06

Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79

Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med (2012) 10.64

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol (2007) 10.19

Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92

The ClinicalTrials.gov results database--update and key issues. N Engl J Med (2011) 9.83

ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation (2006) 9.83

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 9.80

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J (2007) 9.80

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74

Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol (2009) 9.59

Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40

Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation (2002) 9.04

Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol (2008) 9.02

ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation (2008) 8.94

Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA (2010) 8.90

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 8.81

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Third universal definition of myocardial infarction. Circulation (2012) 8.47

ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol (2006) 8.36

Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11

AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01

Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81

Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation (2004) 7.72

2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54

Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation (2006) 7.16

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12

A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94

Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2010) 6.93

Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med (2011) 6.90

Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86

Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85

Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev (2009) 6.85

Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84

ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol (2008) 6.78

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation (2007) 6.78

Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63

Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke (2009) 6.62

2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2009) 6.61

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol (2004) 6.50

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39

2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32

Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA (2012) 6.29